Overview
LLY market data
Price History
LLY price chart · 1M
- O
- 1,151.57
- H
- 1,158.23
- L
- 1,138.53
- C
- 1,148.47
- Vol
- 83,812.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1,151.57
- Previous Close
- $1,159.54
- Day High
- $1,158.23
- Day Low
- $1,138.53
- 52 Week High
- $1,292.51
- 52 Week Low
- $941.26
- 7 Day Return
- -2.16%
- 30 Day Return
- -1.64%
- 90 Day Return
- +0.03%
- 1 Year Return
- +19.12%
- Daily Notional Volume
- $96.3M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 40.31 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $22.95 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.43 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.8% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 33.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $712.05 – $1,292.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.1T · P/B 38.29 · P/S 13.52.
Company News
10 captured
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development ProgressGlobenewswire Inc ·
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite LossZacks Investment Research ·
AZN Stock Down 20% in 6 Months: How to Play After Pipeline SetbacksZacks Investment Research ·
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?Zacks Investment Research ·
Vanguard Health Care ETF vs Simplify Health Care ETFThe Motley Fool ·
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B DealZacks Investment Research ·